ROYALTY PHARMA ROYALTY PHARMA Royalty Pharma plc Q3 2022 Financial Results November 8, 2022 2 Forward Looking Statements & Non-GAAP Financial Information This presentation has been prepared by Royalty Pharma plc (the "Company"), is made for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities. The information set forth herein does not purport to be complete or to contain all of the information you may desire. Statements contained herein are mad ...

Royalty Pharma plc (NASDAQ:RPRX) Q3 2022 Results Earnings Conference Call November 8, 2022 8:00 AM ET Company Participants George Grofik - SVP, Head, IR & Communications Pablo Legorreta - Founder and Chief Executive Officer Marshall Urist - Executive Vice President and Head of Research and Investments Terry Coyne – Executive Vice President and Chief Financial Officer Christopher Hite - Executive Vice President and Vice Chairman Conference Call Participants Geoff Meacham - Bank of America Merrill Lynch Chris ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-39329 Royalty Pharma plc (Exact name of registrant as specified in its charter) England and Wales 98-1535773 (State or other ju ...

Royalty Pharma plc (NASDAQ:RPRX) Q2 2022 Earnings Conference Call August 4, 2022 8:00 AM ET Company Participants George Grofik - SVP, Head, IR & Communications Pablo Legorreta - Founder & CEO Marshall Urist - EVP & Head, Research & Investments Terry Coyne – EVP & CFO Chris Hite - Vice Chairman Conference Call Participants Chris Shibutani - Goldman Sachs Chris Schott - J.P. Morgan Terence Flynn - Morgan Stanley Andrew Baum - Citi Steven Scala - Cowen Geoff Meacham - Bank of America Mike DiFiore - Evercore As ...

ROYALTY PHARMA ROYALTY PHARMA Royalty Pharma plc Q2 2022 Financial Results August 4, 2022 2 Forward Looking Statements & Non-GAAP Financial Information This presentation has been prepared by Royalty Pharma plc (the "Company"), is made for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities. The information set forth herein does not purport to be complete or to contain all of the information you may desire. Statements contained herein are made ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-39329 Royalty Pharma plc (Exact name of registrant as specified in its charter) England and Wales 98-1535773 (State or other juri ...

Royalty Pharma plc (NASDAQ:RPRX) Q1 2022 Earnings Conference Call May 5, 2022 8:00 AM ET Company Participants George Grofik - Senior Vice President, Head-Investor Relations & Communications Terry Coyne - Executive Vice President & Chief Financial Officer Marshall Urist - Head, Research & Investments Chris Hite - Vice Chairman Conference Call Participants Chris Schott - JPMorgan Terence Flynn - Morgan Stanley Chris Shibutani - Goldman Sachs Geoff Meacham - Bank of America Umer Raffat - Evercore Andrew Baum - ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-39329 Royalty Pharma plc (Exact name of registrant as specified in its charter) England and Wales 98-1535773 (State or other jur ...

Royalty Pharma plc (NASDAQ:RPRX) Q4 2021 Earnings Conference Call February 15, 2022 8:00 AM ET Company Participants George Grofik – Senior Vice President, Head-Investor Relations and Communications Pablo Legorreta – Founder and Chief Executive Officer Jim Reddoch – Executive Vice President, Co-Head-Research and Investments and Chief Scientific Officer Marshall Urist – Executive Vice President, Co-Head of Research and Investments Terry Coyne – Executive Vice President and Chief Financial Officer Conference ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-39329 Royalty Pharma plc (Exact name of registrant as specified in its charter) England and Wales 98-1535773 (State or other jurisdic ...